Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T14:52:20.551Z.
Calculation as of: 2026-10-06T14:52:20.551Z.
Quote observation: 2026-10-06T14:50:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9a1dfb6c252c1cf241c11dff63bdf10e98668db23039cc4017602387c5996572
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Genelux Corporation
Market Cap
$114.79M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| Genelux Corporation (GNLX) | $114.79M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $113.83M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.32M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.95M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $113.30M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $117.05M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $112.19M | N/A |
| BGM Group Ltd. (BGM)vs › | $111.14M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.72M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
